Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • NCI-CCC Tumor Board Question • University of Michigan • NCI-CCC Lymphoma Tumor Board Question
How would you treat relapsed/refractory T cell/histiocyte rich large B cell lymphoma after 2nd line therapy?
Given the unique considerations with this subtype of poor response to CART and the rare malignant cells on pathology, how does this impact your treatment decision?